Standard IV rehydration

ApprovedSmall molecule

TThe Hospital for Sick Children

Standard IV rehydration is one of 21 small molecule programs targeting Gastroenteritis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GastroenteritisActive, not recruiting

GastroenteritisApproved

Active, not recruiting

Competition

Competitive Landscape

32 competitors in Gastroenteritis

#DrugCompanyPhaseTrials

Zofran

Novartis

Approved

8 2

Cipro

Bayer

Approved

—3

Reglan

IIstituto Clinico Humanitas

Approved

—4

Hyoscine-N-Butylbromide

Boehringer Ingelheim

Approved

2 5

Dimenhydrinate

SSt. Justine's Hospital

Approved

1 6

Rotarix ™

GSK

Phase 3

1 7

Prulifloxacin

Merck & Co.

Phase 3

1 8

Domperidone

Johnson & Johnson

Phase 3

1 9

Xolair

Roche

Phase 2

1 10

Dipyrone

EEMS

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Gastroenteritis1 trial

Emergency Department Rapid Intravenous Rehydration (RIVR) for Pediatric Gastroenteritis

Completed·TThe Hospital for Sick Children·Phase 4·NCT00392145·226 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Standard IV rehydration. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Standard IV rehydration compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Standard IV rehydration. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Hospital for Sick Children company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: TThe Hospital for Sick Children

Standard IV rehydration

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Gastroenteritis1 trial

References

Drug Info

Quick Facts

Related News